STAT5d
Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials
AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion ...
Crain's Chicago Business4d
AbbVie tumbles after new schizophrenia drug fails trials
their biggest intraday drop since March 2020. The stock had gained 29% this year through Friday’s close, outperforming a 26% rise in the S&P 500. “This outcome is a real dagger” for AbbVie ...
AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
Positive Outlook on AbbVie: Geoff Meacham’s Buy Rating and Potential of Emraclidine Amid Schizophrenia Trial Challenges
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
AbbVie Buy Rating Affirmed Despite Emraclidine Setback, Driven by Skyrizi and Rinvoq Growth
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
MedPage Today25d
Laser Trabeculoplasty Tops Eye Drops as Frontline Treatment for Glaucoma
The advantage of SLT over eye drops occurred despite ongoing treatment ... Lind disclosed relationships with AbbVie, Heru, Nicox, and SpyGlass. Source Reference: Montesano G, et al "Six-year ...